Literature DB >> 17119657

[Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital].

Cristiane Valle Tovo, Diogo Edele Dos Santos, Angelo Zambam de Mattos, Paulo Roberto Lerias de Almeida, Angelo Alves de Mattos, Breno Riegel Santos.   

Abstract

BACKGROUND: Hepatitis B and C viruses and human immunodeficiency virus share the same route of transmission, and the prevalence of HBV and HCV infection in patients infected with HIV is greater than it is in the general population. AIM: To determine the prevalence of hepatitis B and C markers in a population of patients with HIV as well as the risk factors involved. PATIENTS AND METHODS: From 5,870 registration forms of patients with HIV of an Infectology Unit, 587 were randomly selected. From these, the 343 which had investigated the presence of any hepatitis B (HBsAg, anti-HBc or anti-HBs) or C (anti-HCV) marker were retrospectively analyzed.
RESULTS: HBsAg was positive in 14/306 (4.6%), anti-HBs was positive in 40/154(26.0%), and anti-HBc in 79/205 (38.5%). The anti-HCV test was reactive in 126/330 (38.2%). HBV and HCV co-infection was observed in 7 of the 296 patients who had both HBsAg and anti-HCV tests (2.4%). For those who were HBsAg positive, the main exposure factor was homosexual intercourse (50.0%). For those who were anti-HCV reactive, the main risk factor was intravenous drug use (75.3%). In the HIV mono-infected (185 patients), the most prevalent exposure risk factor was promiscuous heterosexual practices or sexual intercourse with a spouse infected with HIV (83 patients - 44.9%).
CONCLUSION: In our environment HBV-HIV and HCV-HIV co-infections are frequent, a greater relevance being observed in the association between HCV and HIV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119657     DOI: 10.1590/s0004-28032006000200002

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  10 in total

1.  Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years.

Authors:  Helen M Chun; Ann M Fieberg; Katherine Huppler Hullsiek; Alan R Lifson; Nancy F Crum-Cianflone; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; William P Bradley; Brian K Agan; Michael L Landrum
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

2.  Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.

Authors:  Maria Cassia Mendes-Correa; João R R Pinho; Michele S Gomes-Gouvea; Adriana C da Silva; Cristina F Guastini; Luiz G Martins; Andréa G Leite; Mariliza H Silva; Reinaldo J Gianini; David E Uip
Journal:  BMC Infect Dis       Date:  2011-09-20       Impact factor: 3.090

3.  T-Cell Response to Hepatitis B Core Antigen: Identification of Prior Exposure to and Confirmatory Testing for Screening for Anti-HBc.

Authors:  Patricia Araujo; Roger Y Dodd; Flavia Latinni; Renata Souza; Ricardo Diaz; Jose Augusto Barreto
Journal:  J Biomark       Date:  2013-12-03

Review 4.  Seroprevalence of hepatitis C virus among people living with HIV/AIDS in Latin America and the Caribbean: a systematic review.

Authors:  Fatima Mitiko Tengan; Karim Yakub Ibrahim; Bianca Peixoto Dantas; Caroline Manchiero; Mariana Cavalheiro Magri; Wanderley Marques Bernardo
Journal:  BMC Infect Dis       Date:  2016-11-09       Impact factor: 3.090

5.  Prevalence of hepatitis B in people living with HIV/AIDS in Latin America and the Caribbean: a systematic review and meta-analysis.

Authors:  Fatima Mitiko Tengan; Edson Abdala; Marisa Nascimento; Wanderley Marques Bernardo; Antonio Alci Barone
Journal:  BMC Infect Dis       Date:  2017-08-24       Impact factor: 3.090

6.  Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.

Authors:  Lucy Platt; Clare E French; Catherine R McGowan; Keith Sabin; Erin Gower; Adam Trickey; Bethan McDonald; Jason Ong; Jack Stone; Philippa Easterbrook; Peter Vickerman
Journal:  J Viral Hepat       Date:  2019-12-22       Impact factor: 3.728

7.  Seroprevalence of transfusion-transmissible infectious diseases at a hemotherapy service located in southwest Bahia, Brazil.

Authors:  Kelly Almeida Andrade Ferreira Rebouças; Flávio Marinho Narici; Manoel Neres Santos Junior; Nayara Silva de Macêdo Neres; Márcio Vasconcelos Oliveira; Cláudio Lima Souza
Journal:  Hematol Transfus Cell Ther       Date:  2019-06-17

8.  Clinical outcome of a patient cohort with acute hepatitis B.

Authors:  Laura Alves de Souza; Angelo Alves de Mattos; Maristela Fiorini; Polyanna Ribeiro; Cristiane Valle Tovo
Journal:  Clinics (Sao Paulo)       Date:  2013-05       Impact factor: 2.365

9.  Immune restoration in human immunodeficiency virus and hepatitis C virus coinfected patients after highly active antiretroviral therapy.

Authors:  Vicente Sperb Antonello; Marcelo Campos Appel-da-Silva; Dimas Alexandre Kliemann; Breno Riegel Santos; Cristiane Valle Tovo
Journal:  Braz J Infect Dis       Date:  2013-07-04       Impact factor: 3.257

Review 10.  Prevalence of human immunodeficiency virus/hepatitis C virus co-infection in Brazil and associated factors: a review.

Authors:  Valdete Meurer Kuehlkamp; Fabiana Schuelter-Trevisol
Journal:  Braz J Infect Dis       Date:  2013-05-13       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.